Censors jump into action as China's latest vaccine scandal ignites

Bs_logoImage
AFP Beijing
Last Updated : Jul 22 2018 | 8:35 PM IST

Chinese censors today deleted articles and postings about the vaccine industry as an online outcry over the country's latest vaccine scandal intensified.

Regulators said last week that they had halted production of a rabies vaccine at a large pharmaceutical company in the northeast after finding fabricated records and other problems during an inspection.

It was just the latest in a series of health and safety scandals which have fuelled fear over the safety of basic food and medicine and anger at regulators asleep on the job.

China's censors and regulators struggled to stay abreast of the public's response, deleting posts on WeChat as state media tried to take control of the narrative.

On Sunday night China's Food and Drug Administration (CFDA) announced it had ordered all production stopped at the vaccine maker and launched an investigation.

Changchun Changsheng Biotechnology is China's second largest maker of the rabies vaccine and a subsidiary of a large publicly-traded vaccine maker.

Anxiety grew over the weekend as an essay alleging corruption and murky practices in the vaccine industry spread across WeChat. Netizens reposted the self-published essay as censors swooped in to delete the content.

The CFDA said last week that the problematic rabies vaccine had not left Changsheng's factory.

The company said in a stock exchange filing Sunday that it had already halted production of another vaccine -- for diphtheria, tetanus and pertussis -- which regulators found last year to be sub-standard and which had also become the focus of public attention.

Still the action aroused concern that other problematic vaccines had already been administered to children. In Beijing, an unnamed official at the Center for Disease Control and Prevention told local website The Paper that parents in China's capital need not worry: "Beijing does not have either of these two vaccines in question, the public can be at ease."

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 22 2018 | 8:35 PM IST